Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cost-Effectiveness Studies Support Medtronic's HeartWare HVAD

Executive Summary

A cost-effectiveness analysis of the LATERAL trial shows patients treated with Medtronic’s HeartWare HVAD through the less-invasive thoracotomy procedure incurred lower hospitalization and medical supply costs than patients implanted with a ventricular assist device through the traditional sternotomy approach. Another new analysis shows HeartWare HVAD is more cost-effective than ventricular assist devices of the past.

You may also be interested in...



Cardiovascular Sales & Earnings Roundup: Medtronic TAVR Disappoints While Abbott And Boston Scientific See Structural Success In 2019

The top five cardiovascular device companies, as ranked by Medtech Insight’s MTI 100, have reported their sales and earnings for the last quarter of the calendar year 2019. Here are the highlights from the most recent presentations from Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences and Terumo.

ENDURANCE Analysis Shows Blood-Pressure Management Reduces Stroke Risk In VAD Patients

A post-hoc analysis of the combined data from the ENDURANCE and ENDURANCE Supplemental trials shows a relationship between severely disabling stroke and one-year mortality in patients treated with Medtronic’s HeartWare HVAD as well as other left-ventricular assist devices (LVAD), including Abbott’s HeartMate II, and that blood-pressure control significantly reduces the risk of stroke events from six-months to two-years post-implant.

Clinical Data Double-Boost Supports Medtronic's HeartWare Investment

Results of the LATERAL trial presented at the recent ISHLT conference show Medtronic's HVAD can be implanted safely through a thoracotomy procedure instead of the standard sternotomy approach, which is far more invasive. At the same meeting, subset data from the ENDURANCE trial confirms that the sickest heart-failure patients treated with HVAD have similar outcomes as less sick patients, and results of the ENDURANCE Supplement show that blood pressure management minimizes the risk of stroke with HVAD.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT124917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel